PRMT5: a Putative Oncogene and Therapeutic Target in Prostate Cancer

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2021 Apr 15

PMID 33854218

Citations 23

Authors

Elena Beketova

Jake L Owens

Andrew M Asberry

Chang-Deng Hu

Affiliations

Soon will be listed here.

Abstract

Protein arginine methyltransferase 5 (PRMT5) was discovered two decades ago. The first decade focused on the biochemical characterization of PRMT5 as a regulator of many cellular processes in a healthy organism. However, over the past decade, evidence has accumulated to suggest that PRMT5 may function as an oncogene in multiple cancers via both epigenetic and non-epigenetic mechanisms. In this review, we focus on recent progress made in prostate cancer, including the role of PRMT5 in the androgen receptor (AR) expression and signaling and DNA damage response, particularly DNA double-strand break repair. We also discuss how PRMT5-interacting proteins that are considered PRMT5 cofactors may cooperate with PRMT5 to regulate PRMT5 activity and target gene expression, and how PRMT5 can interact with other epigenetic regulators implicated in prostate cancer development and progression. Finally, we suggest that targeting PRMT5 may be employed to develop multiple therapeutic approaches to enhance the treatment of prostate cancer.

Citing Articles

PRMT5 inhibition has a potent anti-tumor activity against adenoid cystic carcinoma of salivary glands.

Mishra V, Singh A, Korzinkin M, Cheng X, Wing C, Sarkisova V J Exp Clin Cancer Res. 2025; 44(1):11.

PMID: 39794830 PMC: 11724466. DOI: 10.1186/s13046-024-03270-x.

TBL2 Promotes Tumorigenesis via PRMT5/WDR77-Mediated AKT Activation in Breast Cancer.

Lu X, Zhang C, Zhu L, Wang S, Zeng L, Zhong W Adv Sci (Weinh). 2024; 11(47):e2400160.

PMID: 39499734 PMC: 11653647. DOI: 10.1002/advs.202400160.

The diel disconnect between cell growth and division in is interrupted by giant virus infection.

Truchon A, Chase E, Stark A, Wilhelm S Front Microbiol. 2024; 15:1426193.

PMID: 39234538 PMC: 11371579. DOI: 10.3389/fmicb.2024.1426193.

PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression.

Yan W, Liu X, Qiu X, Zhang X, Chen J, Xiao K J Clin Invest. 2024; 134(18).

PMID: 39146021 PMC: 11405040. DOI: 10.1172/JCI175023.

Brg1/PRMT5 nuclear complex epigenetically regulates FOXO1 in IPF mesenchymal progenitor cells.

Jbeli A, Yang L, Xia H, Gilbertsen A, Bitterman P, Henke C Am J Physiol Lung Cell Mol Physiol. 2024; 326(3):L344-L352.

PMID: 38252663 PMC: 11281790. DOI: 10.1152/ajplung.00248.2023.

References

Yang Y, Bedford M . Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2012; 13(1):37-50. DOI: 10.1038/nrc3409. View

Krause C, Yang Z, Kim Y, Lee J, Cook J, Pestka S . Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol Ther. 2006; 113(1):50-87. DOI: 10.1016/j.pharmthera.2006.06.007. View

Jahan S, Davie J . Protein arginine methyltransferases (PRMTs): role in chromatin organization. Adv Biol Regul. 2014; 57:173-84. DOI: 10.1016/j.jbior.2014.09.003. View

Stopa N, Krebs J, Shechter D . The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci. 2015; 72(11):2041-59. PMC: 4430368. DOI: 10.1007/s00018-015-1847-9. View

Karkhanis V, Hu Y, Baiocchi R, Imbalzano A, Sif S . Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem Sci. 2011; 36(12):633-41. PMC: 3225484. DOI: 10.1016/j.tibs.2011.09.001. View

Shailesh H, Zakaria Z, Baiocchi R, Sif S . Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer. Oncotarget. 2019; 9(94):36705-36718. PMC: 6291173. DOI: 10.18632/oncotarget.26404. View

Fan Z, Kong X, Xia J, Wu X, Li H, Xu H . The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription. Biochim Biophys Acta. 2016; 1859(5):687-96. DOI: 10.1016/j.bbagrm.2016.03.004. View

Chen H, Lorton B, Gupta V, Shechter D . A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression. Oncogene. 2016; 36(3):373-386. PMC: 5140780. DOI: 10.1038/onc.2016.205. View

La Vignera S, Condorelli R, Russo G, Morgia G, Calogero A . Endocrine control of benign prostatic hyperplasia. Andrology. 2016; 4(3):404-11. DOI: 10.1111/andr.12186. View

10.

Snow O, Lallous N, Singh K, Lack N, Rennie P, Cherkasov A . Androgen receptor plasticity and its implications for prostate cancer therapy. Cancer Treat Rev. 2019; 81:101871. DOI: 10.1016/j.ctrv.2019.05.001. View

11.

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

12.

Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y . Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest. 2001; 80(12):1789-96. DOI: 10.1038/labinvest.3780190. View

13.

Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Naito S . Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. J Urol. 2012; 188(1):300-6. DOI: 10.1016/j.juro.2012.02.2553. View

14.

Beketova E, Fang S, Owens J, Liu S, Chen X, Zhang Q . Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer. Cancer Res. 2020; 80(22):4904-4917. PMC: 7669631. DOI: 10.1158/0008-5472.CAN-20-1228. View

15.

Migliori V, Muller J, Phalke S, Low D, Bezzi M, Mok W . Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 2012; 19(2):136-44. DOI: 10.1038/nsmb.2209. View

16.

Faber P, van Rooij H, Schipper H, Brinkmann A, Trapman J . Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem. 1993; 268(13):9296-301. View

17.

Zhu C, Hou X, Zhu J, Jiang C, Wei W . Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance. Oncol Lett. 2018; 16(3):3140-3144. PMC: 6096223. DOI: 10.3892/ol.2018.9007. View

18.

Bai S, Cao S, Jin L, Kobelski M, Schouest B, Wang X . A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. Oncogene. 2019; 38(25):4977-4989. PMC: 6586509. DOI: 10.1038/s41388-019-0768-8. View

19.

Mongiardi M, Savino M, Bartoli L, Beji S, Nanni S, Scagnoli F . Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells. Sci Rep. 2015; 5:15494. PMC: 4643314. DOI: 10.1038/srep15494. View

20.

Koh C, Bezzi M, Low D, Ang W, Teo S, Gay F . MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015; 523(7558):96-100. DOI: 10.1038/nature14351. View